biostudies-literatureUnknown125Chu X<h4>Background</h4>Tocilizumab, an interleukin-6 receptor inhibitor, is a promising cytoprotective agent selected by the Stroke Preclinical Assessment Network. It showed a protective effect on infarct volume and functional outcomes in animal stroke models.<h4>Methods</h4>In this investigator-initiated, multicentre, randomised, double-blind, placebo-controlled trial, patients with acute ischaemic stroke undergoing EVT were recruited. Eligible patients were randomly assigned (1:1) to receive tocilizumab or placebo treatment. Both patients and investigators were blinded to the treatment assignments. A single dose of tocilizumab (240 mg) or placebo was administered intravenously as soon as possible within 24 h after stroke onset and within 1 h after randomisation. The primary efficacy outcome EBioMedicine106167https://www.ebi.ac.uk/biostudies/studies/S-EPMC12917384biostudies-literatureEffect of IL-6 receptor inhibition on infarct volume after endovascular treatment for ischaemic stroke: a phase 2, randomised, placebo-controlled trial.PMC12917384Wang AWang BDong XWu CWang HZhang SDong QZhang QWang LXiong YWang NGu HLiebeskind DSShang LKang MWen CSu YChen SWang YSun JYuan SLi HLi JLi CChen JBaron JCFeng XFeng YChen LChu XSun WLi RGao QYang YLi SFisher MLu HXu SFeng WYang QYang SLan JLiu HYu LLiu JCao JZhao WMa ZBo HWei WNiu XLiu YDing YZhou CJia XLi AYin YCheng FIRIS investigatorsJi XMa HLiu BLiesz AHan JFang MYe HLiu GfalseEffect of IL-6 receptor inhibition on infarct volume after endovascular treatment for ischaemic stroke: a phase 2, randomised, placebo-controlled trial.<h4>Background</h4>Tocilizumab, an interleukin-6 receptor inhibitor, is a promising cytoprotective agent selected by the Stroke Preclinical Assessment Network. It showed a protective effect on infarct volume and functional outcomes in animal stroke models.<h4>Methods</h4>In this investigator-initiated, multicentre, randomised, double-blind, placebo-controlled trial, patients with acute ischaemic stroke undergoing EVT were recruited. Eligible patients were randomly assigned (1:1) to receive tocilizumab or placebo treatment. Both patients and investigators were blinded to the treatment assignments. A single dose of tocilizumab (240 mg) or placebo was administered intravenously as soon as possible within 24 h after stroke onset and within 1 h after randomisation. The primary efficacy outcome 2026-01-01T00:00:00Z2026 Feb2026-07-16T09:58:43.408Z2026-07-09T10:49:48.276ZS-EPMC129173844168745310.1016/j.ebiom.2026.106167